Biobanking: Technologies and Global Markets

  • ID: 3979000
  • Report
  • Region: Global
  • 163 Pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 5
The Global Market for Biobanking Technologies is Expected to Increase from $198.2 Billion in 2016 to $240.2 Billion in 2021 at a CAGR of 3.9%

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Astrazeneca Ltd
  • Boehringer Ingelheim Gmbh
  • Exiqon Life Sciences
  • Johnson & Johnson Ltd
  • Pfizer Inc
  • MORE

The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.

This report provides:

  • An overview of the global markets for biobanking, the storage of biological samples for the future.
  • Analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021.
  • Detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
  • Breakdowns of the biobanking market by product, disease category, and geographic region or country.
  • New products approved by the FDA, and those products expected to be approved within the forecast period.
  • Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
  • Profiles of the manufacturers of leading products, and their specific product strategies are outlined.

This report entails forecasted and prevailing biobank products within the 2016 to 2021 period. Biobanks play a critical role in the development of new drugs. The document also features new FDA-approved products in 2015 and 2016, as well as those awaiting approval within the forecast period. The 2016 figures in this report are approximated except in cases where reports of exact results have been released; this is attributed to the timing of this report’s release.

Emerging companies and the leading competitors in the prevailing global Biobanks industry are analyzed extensively in this report. The specific product strategies and products of leading drug manufacturers in the market are analyzed and profiled in the report. Biotechnology companies that utilize biobanks to develop new, novel products are also included in the analysis. New products expected to be introduced in the market within the forecast period and their manufacturers, in addition to their impact on the competitive biobank market are discussed in this report. The competitive market environment is evaluated with a unique emphasis on the effect of the new technologies and products on the prevailing patient care standard. Emerging companies and current leaders in the market are profiled and discussed in detail.

Market figures are founded on the revenue level of the manufacturers and forecast done in the 2016-dollar value. Forecast figures exclude inflation. Parameters like the introduction of new products, forecast sales for prevailing products, expanded indications for prevailing products and forecasted changes in the rates of diagnosis, prevalence and scripting for specific diseases are considered when assessing trends.

Forecasts featured in this report for the period between 2016 and 2021 are based on disease category, product and company. The study is organized for an overview of the biobanks market by geography, company and product. The projections are based on country or geographic region. For every disease sub-segment, the global market is evaluated and data provided.

Consumables that do not require prescription from a physician like over-the-counter (OTC) drugs are not covered in this report.

Sales figures are in U.S. dollars, with each reflecting change in revenue performance due to currency fluctuations. Variations in local currencies, however, are not accounted for by the revenue figures.

Unless pointed out, all data on market share in the report are on a global basis.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories Inc.
  • Astrazeneca Ltd
  • Boehringer Ingelheim Gmbh
  • Exiqon Life Sciences
  • Johnson & Johnson Ltd
  • Pfizer Inc
  • MORE

1: Introduction - Complimentary

  • Study Goals And Objectives
  • Reasons For Doing The Study
  • Scope Of Report
  • Intended Audience

2: Summary - Complimentary

  • Table Summary : Global Market For Biobanks By Segment, Through 2021
  • Figure Summary : Global Market For Biobanks By Segment, 2015-2021

3: Overview

  • Current State Of The Industry
  • The Process Of Biobanking
  • Historical Context
  • Drivers Of Biobanks Growth
  • Resistors Of Biobanks Growth
  • Biobanking Trends And Forecast
  • The Role Of Biobanks In Future Biomedical Discoveries

4: Overview Of Biobank Applications

  • Biomarkers
  • Opportunities In Cancer
  • Opportunities In Cardiovascular Disease
  • Opportunities In Neurological Diseases
  • Opportunities In Immunology
  • Other Opportunities Resulting From Biobanks
  • Table 4 : Global Market For Biobanking By Application, Through 2021

5: Current Biobanks Worldwide

  • Overview
  • U.S. Biobanks
  • European Biobanks

6: Disease-Based Biobanks

  • Growth In Disease-Based Biobanks
  • Cancer Biobanks
  • Biobanks For Other Diseases
  • Healthy Sample Biobanks
  • Collaborative Networks

7: Population Based Biobanks

  • Introduction
  • Types Of Population Biobanks
  • Cohort Studies
  • Founder Population Biobanks
  • National Population Biobanks

8: For-Profit Biobank Companies

  • Contract Biobank And Service Providers
  • Biomarker Discovery Companies
  • Pharmaceutical Collections
  • Research Collaborations
  • Clinical Trials

9: The Limitations Of Biobanks

  • Sample Variability
  • Sample Quality
  • Efforts To Increase Harmonization
  • Initiatives To Improve Biobanks

10: Regulatory Dynamics, Intellectual Property, Ethical Considerations

  • Introduction
  • Role Of The Food & Drug Administration
  • Current Regulatory Framework
  • Informed Consent
  • Withdrawal And Ownership
  • Confidentiality
  • Commercialization
  • Fda Guidelines For Biomarker Applications
  • European Medicines Agency
  • Intellectual Property And Competitive Positioning
  • Ethical Considerations
  • Regulatory Implications

11: Biobank Markets Forecast By Segment And Region

  • Summary
  • Geographic Mix

12: Detailed Description Of The Use Of Biomarkers

  • Colorectal Cancer
  • Other Predictive Tests
  • Breast Cancer
  • Test Adoption
  • Triple Negative Breast Cancer
  • Other Novel Biomarkers
  • Lung Cancer
  • Other Predictive Tests
  • Novel Therapies
  • Cardiovascular
  • Central Nervous System
  • Immunology- Autoimmune Diseases
  • Immunology

13: Company Analysis

  • Abbott Laboratories Inc.
  • Affymetrix, Inc.
  • Asterand Plc
  • Astrazeneca Ltd
  • Bayer Schering Pharma Ag
  • Biochain-Genomics
  • Biostorage Technologies, Inc.
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Co
  • Daiichi Sankyo Company, Ltd
  • Eli Lilly And Company
  • Exiqon Life Sciences
  • Glaxosmithkline
  • Johnson & Johnson Ltd
  • Millennium Pharmaceuticals
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc
  • F. Hoffman-La Roche AG
  • Sanofi-Aventis
  • Scipac
  • Takeda Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd.

List Of Tables

Summary Table : Global Market For Biobanks By Segment, Through 2021
Table 1 : Cumulative Number Of Dna Samples Banked In Population-Based Studies - , 1970-2015
Table 2 : Value Of Dna Samples Stored, Through 2021
Table 3 : Nih Sponsored Clinical Trials Conducting Gene Expression Profiling, 2000-2014 -
Table 4 : Global Market For Biobanking By Application, Through 2021
Table 5 : Selected Cancer Biobanks In The U.S.
Table 6 : Global Market For Biomarkers In Late Stage Clinical Use By Therapeutic Area, Through 2021
Table 7 : Application Of Biobanks In Cancer Treatment
Table 8 : Representative Biomarkers In Clinical Use: Oncology
Table 9 : Representative Biomarkers In Clinical Use: Cardiovascular
Table 10 : Representative Biomarkers In Clinical Use: Cns Disease
Table 11 : Representative Biomarkers In Clinical Use: Immunology
Table 12 : Global Major Biobanks Locations, By Country, 1998-2009
Table 13 : Types Of Biobanks
Table 14 : Major Nhlbi Cohort Studies
Table 15 : Examples Of Major Disease-Based Biobanks
Table 16 : Establishments Licensed To Operate Biobanks In The U.K., 2016
Table 17 : Funding Sources For Biobanks Licensed In The U.K.
Table 18 : Composite Funding Methods For Biobanks In Bbmri Countries
Table 19 : Distribution Of Biobanks In Eu Countries
Table 20 : Ownership Of European Biobanks
Table 21 : Access To The European Biobank
Table 22 : Growth In Disease-Based Biobanks By Therapy In The U.S., 2007-2014
Table 23 : Selected Population-Based Cohort Biobanks, 1976-2009
Table 24 : Founder Population-Based Biobanks
Table 25 : Fda Guidelines For Biomarker Applications
Table 26 : Global Annual Patents Filed And Approved With Biomarker Claims By Region, Through 2016
Table 27 : Global Market For Clinical Stage Biomarkers By Services And Products, Through 2021
Table 28 : Summary Of Recent Agreements In Biomarker Delivery
Table 29 : Representative List Of Approved Biomarker Patents In The U.S., Europe And Japan
Table 30 : Global Market For Biobanks By Segment, Through 2021
Table 31 : Global Market Share Of Biobanks By Region, 2015-2021
Table 32 : Current Active Biomarker Trials Ongoing: Oncology
Table 33 : Representative Active Biomarker Trials Ongoing: Breast Cancer, 2007-2009
Table 34 : Representative Active Biomarker Trials Ongoing: Lung Cancer, 2006-2014
Table 35 : Representative Active Biomarker Trials Ongoing: Malignant Melanoma, 2006-2016
Table 36 : Representative Biomarkers In Clinical Use: Cardiovascular, 2010-2014
Table 37 : Representative Biomarkers In Clinical Use: Cns Disease, 2010-2013
Table 38 : Biomarkers/Test For Other Neurological Diseases, 2008-2009
Table 39 : Representative Biomarkers In Clinical Use: Immunology, 2009-2014
Table 40 : Abbott Representative Clinical Trials Involving Biomarkers
Table 41 : Asterand Products Overview By Type Of Biobank
Table 42 : Astrazeneca Representative Clinical Trials Involving Biomarkers
Table 43 : Biochain-Genomics' Products Overview By Type Of Biobank
Table 44 : Biostorage Technologies' Products Overview By Type Of Biobank
Table 45 : Bms Representative Clinical Trials Involving Biomarkers
Table 46 : Eli Lilly Representative Clinical Trials Involving Biomarkers
Table 47 : Exiqon Products Overview By Type Of Biobank
Table 48 : Gsk Representative Clinical Trials Involving Biomarkers
Table 49 : Millennium Products Overview By Type Of Biobank
Table 50 : Merck Representative Clinical Trials Involving Biomarkers
Table 51 : Novartis Representative Clinical Trials Involving Biomarkers
Table 52 : Pfizer Representative Clinical Trials Involving Biomarkers
Table 53 : Roche Representative Clinical Trials Involving Biomarkers
Table 54 : Sanofi-Aventis Representative Clinical Trials Involving Biomarkers
Table 55 : Scipac Products Overview By Type Of Biobank

List Of Figures

Summary Figure : Global Market For Biobanks By Segment, 2015-2021

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories Inc.
  • Affymetrix, Inc.
  • Asterand Plc
  • Astrazeneca Ltd
  • Bayer Schering Pharma Ag
  • Biochain-Genomics
  • Biostorage Technologies, Inc.
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Co
  • Daiichi Sankyo Company, Ltd
  • Eli Lilly And Company
  • Exiqon Life Sciences
  • Glaxosmithkline
  • Johnson & Johnson Ltd
  • Millennium Pharmaceuticals
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc
  • F. Hoffman-La Roche AG
  • Sanofi-Aventis
  • Scipac
  • Takeda Pharmaceuticals Ltd
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll